THIS WEBSITE USES COOKIES
We use cookies to personalise content, to provide social media features, and to analyse our traffic. By choosing 'allow all cookies', you consent to our cookies.
To find out more, read our privacy policy and cookie policy.

Abbreviations

Abbreviations

GMB

Adult glioblastoma

pHGG

Paediatric high-grade glioma

UNCAN

EU initiative for understanding cancer

MRI

Magnetic resonance imaging 

SOC

Standard of care

I/O

Immuno-oncology

TTF

Tumour treating fields

Highlights from partner talks at EANO 2026

Chiara (image on the right) presented research mapping how the glioblastoma tumour ecosystem changes during treatment. The study, conducted with GLIOMATCH support, identified distinct patterns of change associated with patient outcomes. Chiara also presented a poster on the cellular architecture of newly diagnosed glioblastoma.

Frederik (image on the left) presented the IC4 atlas of patient-derived cell lines, a resource for studying primary and metastatic central nervous system tumours. 

Follow GLIOMATCH on LinkedIn for more information on brain tumour research and updates on our milestones towards improving the clinical outcomes of GBM and pHGG.

More Posts

GLIOMATCH: Explained with Dr. Kathrin Cresswell

In this episode of the GLIOMATCH: Explained video series, Dr. Kathrin Cresswell, Professor of Digital Innovations in Health and Care at the University of Edinburgh, explains how GLIOMATCH is working to ensure the successful use and implementation of its novel data platform. We’ve summarised the interview in this news piece.

GLIOMATCH shares its work at the EU Cancer Mission Showcase in Brussels

On World Brain Tumour Day 2026, GLIOMATCH participated in the European event “Advancing Brain Cancer Research: From policy action to scientific breakthroughs” at the European Parliament in Strasbourg. The event highlighted the urgent need to accelerate brain cancer research, strengthen European collaboration and turn scientific progress into improved care for patients.